Objectives: This study aimed to evaluate the efficacy of anti-interleukin-1 therapeutics for treating knee osteoarthritis (KOA). Our research included interleukin-1 (IL-1) inhibitors, IL-1 antibodies and IL-1 receptor antagonists (IL-1 Ras). Methods: We systematically searched PubMed and Mendeley to find randomized control trials (RCTs) or clinical trials (CTs) of anti-interleukin-1 therapeutics in KOA from 2000 to 2023. The outcomes were changes in pain, function and stiffness scores. The research was conducted between November 2023 and January 2024. The risk of bias was assessed using Cochrane Risk of Bias tool RoB 2. Results: Analysis of the nine included studies showed a statistically significant difference in terms of the pain relief group (SMD = −0.20, 95% CI: −0.39 to −0.01, p = 0.0348), physical function improvement (SMD = −0.20, 95% CI: −0.39 to 0.00, p = 0.0479) and stiffness reduction (SMD = −0.22, 95% CI: −0.43 to 0.00, p = 0.0475) between anti-IL-1 therapeutics and placebo or nonsteroidal anti-inflammatory drugs (NSAIDs). However, when we separately analysed placebo and NSAIDs subgroups, the statistical significance was observed only in the placebo group. Our article was limited by the quality of the included RCTs. Two of the included trials were of poor methodological quality, and five showed selective reporting. Conclusions: The results of our study suggest that anti-IL-1 therapeutics might have better efficacy in KOA treatment than placebo or NSAIDs; yet, taking into account the limited availability of studies and data concerning anti-IL-1 in osteoarthritis treatment, we think that more high-quality RCTs on this subject are needed.

Fatigue is a prevalent and debilitating symptom in rheumatic diseases such as rheumatoid arthritis and psoriatic arthritis. Despite advances in reducing inflammation through treatments, fatigue often persists, underscoring its multifactorial etiology. A possible link between the persistent inflammation observed in rheumatic diseases and the onset of fatigue has been suggested. The discovery that skeletal muscles also secrete cytokines and myokines, has opened new avenues for research. This narrative review explores current mechanistic insights and evidence on the dural role of myokines in exacerbating or alleviating fatigue, particularly in the context of physical activity and chronic inflammation. Key myokines such as interleukin-6 (IL-6), myostatin, interleukin-15 (IL-15), brain-derived neurotrophic factor (BDNF), and irisin are examined for their influence on muscle-brain communication, neuroinflammation, and systemic metabolic processes. The findings highlight the potential of targeted myokine modulation as a therapeutic strategy for fatigue management.

Objectives: In this study, our aim is to summarise the available data on the correlation between sarcopenia and sleep disturbances as a consequence of changes in the myokine concentrations. Methods: Our research was conducted by searching through PubMed, Mendeley and Google Scholar. In our analysis, 63 studies are included from the years 2011 to 2025. Among these studies, there are clinical trials, cross-sectional studies, reviews, systematic reviews and meta-analyses. Discussion: There is vast evidence confirming that sleep disturbances are more common among sarcopenic patients. On the other hand, sarcopenia is frequently observed among people with worse quality of sleep. It is also well documented that sarcopenia leads to changes in the myokine serum concentrations, and similar changes are observed among people suffering from sleep disturbances. Sarcopenic patients have lower levels of irisin, BDNF (brain-derived neurotrophic factor), meteorin and IL-15 (interleukin 15) and higher concentrations of FGF-21 (fibroblast growth factor 21) and interleukins 1β, 6 and 10. Lower levels of irisin, BDNF and meteorin, and higher levels of FGF-21 and interleukins 6 and 10, lead to sleep disturbances, like insomnia, reduction of REM (rapid eye movement) sleep time and lower slow-wave activity during the NREM (non-rapid eye movement) sleep phase. These changes are also observed in obstructive sleep apnea (OSA). More severe OSA is correlated with lower levels of irisin and meteorin and higher levels of FGF-21 and interleukins 6 and 8. Conclusions: Taking into account the similarities in the myokine concentration changes in sarcopenia and in sleep disturbances, it may be concluded that alterations in the myokine levels induced by sarcopenia provoke sleep disturbances. However, it is necessary to further investigate these correlations to understand them better.

Introduction: The autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is a rare condition caused by an immune response associated with over-reactivity of the immune system, triggered by adjuvants. The most common adjuvants are aluminium salts but can also be bioimplants or infectious agents. It may lead to the development of various autoimmunologic diseases. Case Report: In the following article, we present the case of a 26-year-old woman who developed SLE likely induced by ASIA syndrome after the aesthetic medicine procedures. The patient was admitted because of arthralgia and fever. She also presented with a butterfly-shaped erythema on her face and erythematous and infiltrative skin lesions on the posterior surface of the thighs and buttocks. We performed numerous diagnostic tests, including laboratory tests, immunological tests, imaging diagnostics such as chest X-ray and USG of the abdomen and joints, and the biopsy of the skin lesion on the left thigh. The results of the diagnostic process led us to diagnose SLE. The patient fulfilled the ACR/EULAR 2019 classification criteria of the SLE. Laboratory results also led to the diagnosis of autoimmune haemolytic anaemia. Due to exposure to numerous adjuvants like tattoo ink, hyaluronic acid, and piercing and the development of the delayed inflammatory reaction (DIR) to hyaluronic acid (HAF), the patient also fulfilled the criteria of ASIA. In the treatment process we applied antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), steroids, hydroxychloroquine, and cyclosporine. The treatment resulted in an improvement in the general condition, resolution of swelling and joint pain, and improvement in skin lesions. Conclusions: ASIA syndrome after bioimplantation is still underdiagnosed, probably due to ignorance or diagnostic difficulties, as symptoms are uncharacteristic and there is no immunological marker for this syndrome. In addition, as in the presented case, it can develop several years after the procedure, and it is difficult for both patient and physician to become aware of the connection. Early diagnosis requires a multidisciplinary approach and may require immunosuppressive treatment in specific cases.

Cardiovascular diseases, which are among the most common diseases of the population and among the leading causes of death, are a constant topic of many research centers. A deeper understanding of their pathogenesis may contribute to the development of innovative diagnostic and therapeutic techniques. Recently, the role of myokines—a group of cytokines secreted mainly by muscle cells—has been increasingly emphasized in the development of these diseases. Both their excess and deficiency can cause undesirable effects that are involved in the pathomechanism of these diseases. In this review, we focus on the latest studies on the role of myonectin, irisin, musclin, follistatin-like1 (FSTL1), dermcidin, apelin, and myostatin in the pathogenesis of coronary artery disease, heart attack, heart failure, and hypertension. In particular, we look at myostatin and irisin in the context of the development of heart failure and decreased levels of apelin with higher cardiovascular risk in a group of patients with rheumatoid arthritis.